JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mubashar, M.
Right arrow Articles by Peters, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mubashar, M.
Right arrow Articles by Peters, A. M.

99mTc-Sestamibi Imaging in the Assessment of Toremifene as a Modulator of Multidrug Resistance in Patients with Breast Cancer

Muhammad Mubashar, PhD;1, Kevin J. Harrington, PhD;2, Khurram S. Chaudhary, PhD;3, El-Nasir Lalani, PhD;3, Gordon W. Stamp, MD;3, Dudley Sinnett, MD;4, Daphne M. Glass, DNM;1 and A. Michael Peters, MD1

1 Department of Imaging, Hammersmith Hospital, London, United Kingdom
2 Oncology Unit, Imperial Cancer Research Fund, Hammersmith Campus, London, United Kingdom
3 Department of Histopathology, Hammersmith Hospital, London, United Kingdom
4 Department of Surgery, Charing Cross Hospital, London, United Kingdom



View larger version (60K):

[in a new window]
  		FIGURE 1. Immunohistochemical staining patterns for Pgp in breast cancer. (A) Negative, scored as 0. (B) Positive, scored as 1. (C) Strongly positive, scored as 3.

 


View larger version (90K):

[in a new window]
  		FIGURE 2. 99mTc-Sestamibi images of breast cancer obtained 20 min (early) and 120 min (late) after injection of radiotracer. (A) Same patient as in Figure 1A with tumor showing T/B that increased from 1.65 to 1.99. (B) Same patient as in Figure 1C with tumor showing T/B that decreased from 2.25 to 1.52.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2002 by the Society of Nuclear Medicine.